Chart of the Week: Hepatitis C – Gilead Wins

In honor of Gilead’s newly approved, and cheaper, hepatitis C drug we decided to show the biomarker, trial and company landscape for hepatitis C. You can read more about Gilead’s new drug here, here and here. Purple: Company Red: Trials Blue: Biomarkers...

Chart of the Week: Value Network of Healthcare

We are mildly obssessed with our customers and the markets into which we sell BiomarkerBase™.  We have been thinking lately about the value chain in healthcare and have concluded that, like most industries, it’s quite complicated.  We have tried to represent the...

Chart of the Week: Biopharma Players in Alzheimers

We’ve published a few “graphs” illustrating topics interesting to us.  Last month published a graph showing Celgene’s biomarker and trial activities.  More recently we published a biomarker and trial landscape graph for Alzheimer’s...

Chart of the Week: Update: Unique Biomarkers in Pharma

On January 29th, we posted a CotW outlining the top 10 pharma companies by number of unique biomarkers those companies are using in trials.  We thought it was about time to update that chart and expand it to the top 25 pharma companies. Interesting facts to note:...